Steven Batki, MD
Working Title
Professor Emeritus
Biography
Steven L. Batki, M.D. is Professor of Psychiatry, in Residence, at the University of California, San Francisco (UCSF) School of Medicine and Chief of the Substance Abuse Programs and Director of the Addiction Psychiatry Research Program at the San Francisco VA Medical Center (SFVAMC), where he also directs the UCSF Addiction Psychiatry Fellowship Program. Dr. Batki is engaged in addiction research, training, and clinical services.
Steven L. Batki, M.D. is Professor of Psychiatry, in Residence, at the University of California, San Francisco (UCSF) School of Medicine and Chief of the Substance Abuse Programs and Director of the Addiction Psychiatry Research Program at the San Francisco VA Medical Center (SFVAMC), where he also directs the UCSF Addiction Psychiatry Fellowship Program. Dr. Batki is engaged in addiction research, training, and clinical services.
Dr. Batki’s research and clinical interests include pharmacologic treatment for addiction to alcohol, opioids, and stimulants. His work focuses on psychiatric and medical disorders that co-occur with addiction, such as such as PTSD, traumatic brain injury (TBI), schizophrenia, and HIV/HCV. He has published extensively on clinical research in addiction and co-occurring disorders. He chaired the SAMSHA CSAT Treatment Improvement Protocol No. 37, Substance Abuse Treatment for Persons with HIV/AIDS, and Treatment Improvement Protocol No. 43, Medication-Assisted Treatment for Opioid Dependence.
Dr. Batki's current research is supported by the Department of Defense and NIDA. His DoD projects are examining the effectiveness of pharmacotherapy for alcohol use disorders in veterans with posttraumatic stress disorder (PTSD) as well as in veterans with mild traumatic brain injury (TBI). Dr. Batki is also conducting NIDA-funded research on the pharmacotherapy of methamphetamine dependence. Recently completed NIDA and NIAAA work has included the study of hepatitis C treatment in injection drug users and the pharmacological treatment of alcohol dependence in schizophrenia.
Dr. Batki’s research and clinical interests include pharmacologic treatment for addiction to alcohol, opioids, and stimulants. His work focuses on psychiatric and medical disorders that co-occur with addiction, such as such as PTSD, traumatic brain injury (TBI), schizophrenia, and HIV/HCV. He has published extensively on clinical research in addiction and co-occurring disorders. He chaired the SAMSHA CSAT Treatment Improvement Protocol No. 37, Substance Abuse Treatment for Persons with HIV/AIDS, and Treatment Improvement Protocol No. 43, Medication-Assisted Treatment for Opioid Dependence.
Dr. Batki's current research is supported by the Department of Defense and NIDA. His DoD projects are examining the effectiveness of pharmacotherapy for alcohol use disorders in veterans with posttraumatic stress disorder (PTSD) as well as in veterans with mild traumatic brain injury (TBI). Dr. Batki is also conducting NIDA-funded research on the pharmacotherapy of methamphetamine dependence. Recently completed NIDA and NIAAA work has included the study of hepatitis C treatment in injection drug users and the pharmacological treatment of alcohol dependence in schizophrenia.
- Residency, - School of Medicine, University of California, San Francisco
Benzazepines
Alcoholism
Substance-Related Disorders
Binge Drinking
Craving
Amphetamine-Related Disorders
Methadone
Narcotics
Narcotic Antagonists
Naltrexone
Methamphetamine
Buprenorphine
Stress Disorders, Post-Traumatic
Homosexuality, Male
Schizophrenia
Psychopharmacology Addictive Disorders
PTSD
Alcohol Addiction
Stimulant Addiction
Impulsivity
Opioid Addiction
Traumatic Brain Injury
September 20, 2018 - May 31, 2024 - Non-Invasive Neuromodulation Device for the Treatment of Alcohol Use Disorder , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: R44AA027188
February 1, 2013 - January 31, 2019 - Mirtazapine for the treatment of methamphetamine dependence among MSM with high-r , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01DA034527
June 1, 2011 - July 31, 2017 - Naltrexone for the treatment of Actively-Using Met-Dependent MSM with High-Risk B , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01DA031678
September 29, 1994 - May 31, 2016 - Treatment for Complex Patients: Continuing and Extended Care , Co-Investigator . Sponsor: NIH, Sponsor Award ID: P50DA009253
September 26, 2003 - June 30, 2010 - Improving Hepatitis C Treatment in Injection Drug Users , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01DA016764
April 1, 2003 - March 31, 2009 - Naltrexone Treatment of Alcohol Abuse in Schizophrenia , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01AA013655
October 1, 1974 - November 30, 2007 - General Clinical Research Center , Co-Investigator . Sponsor: NIH, Sponsor Award ID: M01RR000083
February 20, 1998 - December 31, 2002 - PHARMACOTHERAPY OF METHAMPHETAMINE DEPENDENCE , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01DA011397
February 1, 1978 - August 31, 2000 - DRUG DEPENDENCE CLINICAL RESEARCH PROGRAM , Co-Investigator . Sponsor: NIH, Sponsor Award ID: P50DA001696
August 1, 1994 - June 30, 1998 - TUBERCULOSIS CHEMOPROPHYLAXIS IN INJECTION DRUG USERS , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R01DA008526